- GI Partners has completed the acquisition of the CDMO and Cell Solutions businesses from Charles River Laboratories, creating a new company called Rose BioSolutions.
- Rose Bio will provide end-to-end cell and gene therapy manufacturing services across plasmid DNA, viral vectors, cell therapy, and cellular starting materials.
GI Partners has completed the acquisition of the Contract Development and Manufacturing Organization and Cell Solutions businesses from Charles River Laboratories International, forming a new company named Rose BioSolutions.
Rose Bio will operate as an independent organization focused on advanced therapy development and manufacturing services. According to the company, its capabilities span plasmid DNA, viral vector manufacturing, cell therapy production, and cellular starting materials used in research and therapeutic development.
The transaction is intended to support Rose Bio’s growth strategy in the cell and gene therapy sector. GI Partners stated that the company will invest in operational capabilities, infrastructure, innovation, and manufacturing efficiency to support development timelines and expand advanced therapy services. The company said the business is structured to provide end-to-end CDMO and contract manufacturing support from starting materials through finished therapies.
“Rose Bio fills a gap in the market for a truly end-to-end partner where every step, from starting materials to finished therapy, is part of a single, comprehensive offering.”
Dave Kreter, Managing Director and Head of Healthcare Investments at GI Partners
Rose Bio stated that it plans to support increasing demand for advanced therapies through integrated manufacturing and development services. Ahmad Hussin, Global Head of CDMO and Chief Operating Officer at Rose Bio, said the company combines cellular starting material capabilities with manufacturing expertise across cell therapies, viral vectors, and plasmid DNA to support customers advancing therapeutic programs.
